BRPI0517924A - formas polimórficas de 6-[2(metilcarbamoil) fenilsufanil]-3-e-[2-(piridin-2-il)etenil] indazol - Google Patents

formas polimórficas de 6-[2(metilcarbamoil) fenilsufanil]-3-e-[2-(piridin-2-il)etenil] indazol

Info

Publication number
BRPI0517924A
BRPI0517924A BRPI0517924-6A BRPI0517924A BRPI0517924A BR PI0517924 A BRPI0517924 A BR PI0517924A BR PI0517924 A BRPI0517924 A BR PI0517924A BR PI0517924 A BRPI0517924 A BR PI0517924A
Authority
BR
Brazil
Prior art keywords
methylcarbamoyl
indazole
ethenyl
pyridin
polymorphic forms
Prior art date
Application number
BRPI0517924-6A
Other languages
English (en)
Inventor
Ryan Marshal Hart
Robert Steven Kania
Michael Ouellette
Zhen Ping Wu
Qiang Ye
Scott Edward Zook
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0517924A publication Critical patent/BRPI0517924A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

FORMAS POLIMóRFICAS DE 6-¢2(METILCARBAMOIL)FENILSULFANIL! -3-E- ¢2- (PIRIDIN-2-IL) ETENIL! INDAZOL" A presente invençào está relacionada a novas formas polimárficas de 6- ¢2- (metilcarbamoil)fenilsulfanil! -3-E-¢2-(piridin-2-il)etenil! indazol, e aos processos para suas preparações. Tais formas polimórficas podem ser um componente de uma composição farmacêutica e podem ser usadas para tratar um distúrbio hiperproliferativo ou uma condição de doença em um mamífero mediada pela atividade da proteína quinase.
BRPI0517924-6A 2004-11-02 2005-10-21 formas polimórficas de 6-[2(metilcarbamoil) fenilsufanil]-3-e-[2-(piridin-2-il)etenil] indazol BRPI0517924A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62466504P 2004-11-02 2004-11-02
PCT/IB2005/003312 WO2006048751A1 (en) 2004-11-02 2005-10-21 Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole

Publications (1)

Publication Number Publication Date
BRPI0517924A true BRPI0517924A (pt) 2008-10-21

Family

ID=35538878

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517924-6A BRPI0517924A (pt) 2004-11-02 2005-10-21 formas polimórficas de 6-[2(metilcarbamoil) fenilsufanil]-3-e-[2-(piridin-2-il)etenil] indazol

Country Status (14)

Country Link
US (1) US20060094763A1 (pt)
EP (1) EP1819696A1 (pt)
JP (1) JP2008518904A (pt)
KR (1) KR20070060145A (pt)
AR (1) AR051945A1 (pt)
AU (1) AU2005300317A1 (pt)
BR (1) BRPI0517924A (pt)
CA (1) CA2586177A1 (pt)
IL (1) IL182580A0 (pt)
MX (1) MX2007005273A (pt)
RU (1) RU2007116150A (pt)
TW (1) TW200630356A (pt)
WO (1) WO2006048751A1 (pt)
ZA (1) ZA200702976B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123223A1 (en) * 2005-05-19 2006-11-23 Pfizer Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
EP4074702A1 (en) * 2007-04-05 2022-10-19 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
KR20140069297A (ko) 2011-09-30 2014-06-09 화이자 인코포레이티드 N-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일-설파닐]-벤즈아미드의 약학 조성물
RU2014116407A (ru) 2011-11-11 2015-12-20 Пфайзер Инк. N-метил-2-[3-((e)-2-пиридин-2-ил-винил)-1н-индазол-6-илсульфанил]-бензамид для лечения хронического миелоидного лейкоза
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN104140414B (zh) * 2013-05-07 2018-12-11 江苏豪森药业集团有限公司 阿昔替尼晶型的制备方法
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
AU2015214390B2 (en) 2014-02-04 2020-05-07 Merck Sharp & Dohme LLC. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
EP4279087A3 (en) 2015-02-26 2024-01-31 Merck Patent GmbH Pd-1 / pd-l1 inhibitors for the treatment of cancer
WO2016178150A1 (en) * 2015-05-05 2016-11-10 Shilpa Medicare Limited Novel polymorphs of axitinib
MX2017016324A (es) 2015-06-16 2018-03-02 Merck Patent Gmbh Tratamientos de combinacion de antagonista de ligando 1 de muerte programada (pd-l1).
CA3039451A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
WO2020003196A1 (en) * 2018-06-28 2020-01-02 Alembic Pharmaceuticals Limited Pharmaceutical composition of axitinib
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2020212253A1 (en) 2019-04-18 2020-10-22 Synthon B.V. Process for preparing axitinib, process for purifying the intermediate 2-((3-iodo-1h-indazol-6-yl)thio)-n-methylbenzamide, process for purifying axitinib via the axitinib hcl salt, solid form of the axitinib hcl salt
EP3965743A1 (en) 2019-05-09 2022-03-16 Synthon B.V. Pharmaceutical composition comprising axitinib
HRP20230800T1 (hr) 2020-03-25 2023-10-27 Ocular Therapeutix, Inc. Očni usadak koji sadrži inhibitor tirozin kinaze
CN113943271B (zh) * 2020-07-15 2023-11-14 鲁南制药集团股份有限公司 一种阿昔替尼晶型及其制备方法
CN112174933A (zh) * 2020-08-07 2021-01-05 天津理工大学 一种阿西替尼富马酸盐的新晶型及其制备方法
CN114685437B (zh) * 2020-12-25 2022-12-09 鲁南制药集团股份有限公司 阿昔替尼与糖精共晶
CN114685436B (zh) * 2020-12-25 2022-12-02 鲁南制药集团股份有限公司 阿昔替尼糖精共晶水合物
CN114685431B (zh) * 2020-12-26 2022-11-29 鲁南制药集团股份有限公司 一种阿昔替尼柠檬酸盐晶型
CN114685435B (zh) * 2020-12-28 2023-01-31 鲁南制药集团股份有限公司 阿昔替尼马来酸盐晶型及其制备
CN114685433B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 一种阿昔替尼香草酸共晶盐及其制备
CN114685432B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 阿昔替尼盐晶型及其制备方法
CN114685438B (zh) * 2020-12-28 2023-06-13 鲁南制药集团股份有限公司 一种阿昔替尼苹果酸新盐
WO2023166418A2 (en) 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof
EP4282415A1 (en) 2022-05-26 2023-11-29 Genepharm S.A. A stable tablet composition of axitinib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Also Published As

Publication number Publication date
CA2586177A1 (en) 2006-05-11
IL182580A0 (en) 2007-07-24
MX2007005273A (es) 2007-07-19
WO2006048751A1 (en) 2006-05-11
KR20070060145A (ko) 2007-06-12
RU2007116150A (ru) 2008-11-10
TW200630356A (en) 2006-09-01
US20060094763A1 (en) 2006-05-04
JP2008518904A (ja) 2008-06-05
AU2005300317A1 (en) 2006-05-11
ZA200702976B (en) 2008-08-27
AR051945A1 (es) 2007-02-21
EP1819696A1 (en) 2007-08-22

Similar Documents

Publication Publication Date Title
BRPI0517924A (pt) formas polimórficas de 6-[2(metilcarbamoil) fenilsufanil]-3-e-[2-(piridin-2-il)etenil] indazol
Austin et al. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease
Morawski et al. ECM in brain aging and dementia
Yang et al. HMGB1 a-box reverses brain edema and deterioration of neurological function in a traumatic brain injury mouse model
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
ATE548363T1 (de) 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
BRPI0920261A8 (pt) Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
MA35437B1 (fr) Proteines de fusion pour le traitement de troubles du metabolisme
MA31090B1 (fr) Derives de dihydropyridine utiles en tant qu'inhibiteurs de la proteine kinase
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
TW200630360A (en) Polymorphs of {5-[3-(4,6-difluoro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine
BRPI0515483A (pt) derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
ES2354824T3 (es) Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas.
BRPI0410563A (pt) derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase
NO20054769L (no) Substituerte fenylalkansyrer
UA92497C2 (ru) Составы, которые содержат пептиды, стимулирующие рецептор эритропоэтина, и их применение
BRPI0517921A (pt) métodos para preparar compostos de indazol
MA31167B1 (fr) Inhibiteurs de l'activite de akt
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
BRPI0813499B8 (pt) compostos pirimidina carboxamidas úteis como inibidores da quinase raf, composição farmacêutica compreendendo os mesmos e método de preparação dos mesmos
NO20071240L (no) Terapeutiske anvendelser av RTP801 inhibitorer
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
GEP20094781B (en) Sulfonamide derivatives for the treatment of diseases
NO20063758L (no) Pyrazolo[1,5-A]pyrimidin-7-yl-amin derivater for anvendelse i behandling av proteinkinase avhengige sykdommer
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.